National Drug Code Directory

Similar documents
DEXAMETHASONE SODIUM PHOSPHATE National Drug Code Directory

MYCAMINE National Drug Code Directory

SODIUM BICARBONATE National Drug Code Directory

PHENYTOIN SODIUM National Drug Code Directory

National Drug Code Directory

National Drug Code Directory

National Drug Code Directory

DIVALPROEX SODIUM National Drug Code Directory

HAVRIX National Drug Code Directory

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG National Drug Code Directory

ANTICOAGULANT CITRATE DEXTROSE A ACD-A National Drug Code Directory

POTASSIUM CITRATE CITRIC ACID CRYSTALS National Drug Code Directory

PRIMAXIN National Drug Code Directory

KETAMINE HYDROCHLORIDE National Drug Code Directory

SHEER COVER MINERAL FOUNDATION National Drug Code Directory

MORPHINE SULFATE National Drug Code Directory

FLUZONE QUADRIVALENT National Drug Code Directory

SUBSYS National Drug Code Directory

DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE National Drug Code Directory

FLUZONE INTRADERMAL QUADRIVALENT National Drug Code Directory

DIANEAL LOW CALCIUM WITH DEXTROSE National Drug Code Directory

PEDIATRIC INFUVITE MULTIPLE VITAMINS FOR INFUSION National Drug Code Directory

FLUCELVAX QUADRIVALENT (PREFILLED SYRINGE) National Drug Code Directory

DAPTACEL National Drug Code Directory

CITRANATAL DHA National Drug Code Directory

O-CAL FA MULTIVITAMIN National Drug Code Directory

FOLET DHA National Drug Code Directory

THYRO T3 RESCUE National Drug Code Directory

ADRENAL SUPPORT National Drug Code Directory

HERPES SIMPLEX PLUS National Drug Code Directory

LYMPH/SPLEEN COMBO National Drug Code Directory

CLEANSE REMEDY WATER National Drug Code Directory

TRANQUIL REMEDY NO. 11 National Drug Code Directory

CALM REMEDY WATER National Drug Code Directory

BUG BITES - ITCH STOPPER National Drug Code Directory

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

ANDA Labeling Question Based Review September 11, 2013 GPhA/FDA ANDA Labeling Workshop/USP User Forum

Physician Injectable Drug List (PIDL) Department for Medicaid Services, HP, and Magellan Rx Management June 1, 2010

Calcium Folinate Solution for Injection

Over-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen

Guidance for Industry

Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program

CENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER: Orig1s000 APPROVAL LETTER

NDA NDA APPROVAL

ANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015

FEB 28 A 9 :09

Teva Pharmaceuticals USA Attention: Scott D. Tomsky Vice President, US Generics Regulatory Affairs 425 Privet Road Horsham, PA 19044

Three-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the

Artesunate 120mg powder for injection (Guilin Pharmaceutical Co., Ltd), MA90 LABELLING. Page 1 of 6

NAVINTA LLC FEB loa II: 2 2. February 9, 2011

Inspections, Compliance, Enforcement, and Criminal Investigations

Artesunate 60 mg for injection WHOPAR part 5 June 2013 (Guilin Pharmaceutical Co., Ltd.), MA051 LABELLING

Withdrawal of Proposed Rule on Supplemental Applications Proposing Labeling Changes for

ORANGE BOOK ORANGE BOOK

Mark M. Yacura. Partner

Caution Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Harmonization effort for OTC monograph in Taiwan. Ms. Hsueh-Yung (Mary) Tai Deputy Director, Division of Medical Product, Taiwan FDA

Brand and Generic Drugs. Educational Objectives. Absorption

International Pharmaceutical Aerosol Consortium on Regulation and Science

Injection Solution APP 100 mg/ml MULTI-DOSE IN 1VIAL, MULTI-DOSE / 20 ml IN 1 VIAL, MULTI-DOSE

InvaGen. FDP..90 fit P(Do47. Citizen petitian

Lamivudine Tablets 150 mg (Macleods Pharmaceuticals Ltd), HA424. WHOPAR Part 5 05/2011, version 1.0 LABELLING. Page 1 of 8

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch

Inspections, Compliance, Enforcement, and Criminal Investigations

RE: Permits under the Arizona Pharmacy Act should not be required for dietary supplements

DEPARTMENT OF HEALTH & HUMAN SERVICES

Gluten in Drug Products and Associated Labeling Recommendations Guidance for Industry

Getting Your Ingredient to Market: Understanding Your Regulatory Options Venable LLP

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.

DESCRIPTION: Each gram of ointment contains 500 units of Bacitracin in a low melting special base containing White Petrolatum and Mineral Oil.

Daniel Fabricant, Ph.D

Drug monograph template for students

Fang-Chi Chang (M.D.,Ph.D.) Center for Drug Evaluation, Taiwan

NAVINTA LLC Fax:

CHAPTER 1 COMMUNITY PHARMACY M.ASHOKKUMAR DEPT OF PHARMACY PRACTICE SRM COLLEGE OF PHARMACY SRM UNIVERSITY

John C. Kim, RPh, JD Senior Director, Regulatory Affairs Ferring Pharmaceuticals Inc. 4 Gatehall Drive 3 rd Floor Parsippany, NJ 07054

Reimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.

WEBINAR 1 CODING FOR FLUZONE VACCINATION CODING AND BILLING FOR VACCINATION WITH FLUZONE, INFLUENZA VACCINES CRACKING THE CODES: UPDATED for

SOMNUS VITM Supplement for sleep and wellness

SUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated

SNuVASivE: 51. 0(k) Premarket Notification Long Lateral Spinal System

LACHMAN CONSULTANT SERVICES, INC STEWART AVENUE, WESTBURY, NY (516) " FAX (516) $,7,1 OVERNIGHT COURIER 11/16/09

Inspections, Compliance, Enforcement, and Criminal Investigations

ANDA Submissions Refuse to Receive for Lack of Proper Justification of Impurity Limits Guidance for Industry

Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications

UNIVERSITY OF BOLTON SCHOOL OF HEALTH AND HUMAN SCIENCES BSC (HONS) PRE-REGISTRATION NURSING EDUCATION (ADULT) SEMESTER ONE EXAMINATION 2016/17

Warnings Allergy alert: Ibuprofen may cause a severe allergic reaction, especially in people allergic to aspirin. Symptoms may include:

APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS

Guideline on the Regulation of Therapeutic Products in New Zealand

AbbVie Inc., et al.; Proposal to Withdraw Approval of Abbreviated New Drug Applications for

Hypertension: Developing Fixed- Dose Combination Drugs for Treatment Guidance for Industry

Science IN THE Public Interest ) ihr nonprofit puhliihc~?/ Nutrition Action FIea!thIcttcr

The proposed rule is significant, and the requirements and exceptions are complex. Key provisions of the proposal are described below.

DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f

Transcription:

The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily. 2017

52544-931-02 INFeD Labeler Actavis Pharma, Inc. of Company corresponding to the labeler code segment of the ProductNDC. NDC Code 52544-931-02 The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC. Proprietary INFeD Also known as the trade name. It is the name of the product chosen by the labeler. 11 Digit NDC Code 52544-0931-02 It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format. Product NDC 52544-931 The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. Product Type Non Proprietary Package Description Marketing Category Application Number HUMAN PRESCRIPTION DRUG Iron Dextran 10 VIAL, SINGLE-DOSE in 1 CARTON (52544-931- 02) > 2 ml in 1 VIAL, SINGLE-DOSE NDA NDA017441 Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the Document Type of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Sometimes called the generic name, this is usually the active ingredient(s) of the product. A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE. Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. part 341 ). For unapproved drugs, this field will be null. - 2 -

Start Marketing Date 19740429 This is the date that the labeler indicates was the start of its marketing of the drug product. Dosage Form Route INJECTION INTRAMUSCULAR; INTRAVENOUS The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. Substance IRON DEXTRAN This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. Strength Number 50 These are the strength values (to be used with units below) of each active ingredient, listed in the same order as the Substance field above. Strength Unit mg/ml These are the units to be used with the strength values above, listed in the same order as the Substance and SubstanceNumber. Pharmaceutical Classes Iron [Chemical/Ingredient],Pare nteral Iron Replacement [EPC],Phosphate Binder [EPC],Phosphate Chelating Activity [MoA] These are the reported pharmaceutical class categories corresponding to the Substances listed above. Status Actual Status Last Update 2016-12-02 The date that a record was last updated or changed. - 3 -

Food and Drug Administration Center for Drug Evaluation and Research Office of Compliance, Immediate Office Drug Registration and Listing Team 10903 New Hampshire Ave Silver Spring, MD 20993-0002 Email: edrls@fda.hhs.gov - 4 -

For all questions regarding this bundle please contact Support@HIPAASpace.com. Also feel free to let us know about any suggestions or concerns. All additional information as well as customer support is available at http://www.hipaaspace.com. - 5 -